During the past decade, Centro de Tratamento de câncer Medradius conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Centro de Tratamento de câncer Medradius" are "Castration-Resistant Prostatic Cancer" (1 trials) and "Metastatic Prostate Cancer" (1 trials). Many other conditions were trialed in "Centro de Tratamento de câncer Medradius" in a lesser frequency.

Most popular intervention types in "Centro de Tratamento de câncer Medradius" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abiraterone Acetate" (1 trials), "New Formulation of Niraparib and Abiraterone Acetate (AA)" (1 trials), "Niraparib" (1 trials), "Placebo" (1 trials) and "Prednisone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Tratamento de câncer Medradius" are 2 trials for "Male" genders.

Currently, there are NaN active trials in "Centro de Tratamento de câncer Medradius". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Centro de Tratamento de câncer Medradius, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Tratamento de câncer Medradius, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".